
Overview
Instrumentation company's fiscal Q2 revenue fell compared to last year
R&D expenses fell 25% as company transitions to saleable products
Outlook
Company sees positive momentum in sales pipeline across global markets
Astrotech emphasizes library capabilities for explosives and narcotics detection
Company strengthens team with new appointments for revenue growth and global scale
Result Drivers
R&D EXPENSES - R&D expenses fell 25% as co transitions to saleable products for EN-SCAN Handheld GC and 1st Detect Tracer 1000 lines
PRODUCT DEPLOYMENT - TRACER 1000 system deployed in 35 locations across 16 countries, indicating market expansion
TEAM STRENGTHENING - Co appointed Scott Bartley as Interim CFO and David Spada as Director of Global Sales to support revenue growth and scaling
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $148,000 |
|
Q2 EPS |
| -$2.34 |
|
Q2 Net Income |
| -$3.93 mln |
|
Q2 Gross Profit |
| $8,000 |
|
Q2 Operating Expenses |
| $3.91 mln |
|
Press Release: ID:nGNX30nlmQ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.